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using Ingenix® data (2002-05). The analysis included elderly individuals aged ≥65 
years (47.9% females) on oral treatment for diabetes (insulin users excluded), 
classified as SU users (n=20,741) and non-users (n=22,114) at baseline. RESULTS: 
During the follow-up, we identified 420 cases of incident hip fractures in the SU 
group and 228 in non-SU group; unadjusted odds ratio (OR) for hip fracture risk 
was 1.98 (95% confidence intervals [CI]:1.69-2.33). In a multivariable logistic 
regression analysis simultaneously accounting for propensity to use SU and for 
potential confounders (age, gender, health insurance, geographic region, CVD, 
stroke, osteoporosis, dementia, hypertension, and use of steroids, 
benzodiazepines, anti-depression, anti-psychotic, anti-convulsant therapy and 
treatment for osteoporosis), the adjusted OR was 1.60 (95%CI: 1.35-1.90). This 
association was similar among men (210 cases; OR=1.68; 95%CI: 1.24-2.26) and 
women (438 cases; OR: 1.56; 95%: 1.27-1.92). In addition, SU users also had higher 
risk of hypoglycemia compared to non-users (5.8% vs. 2.1%). Furthermore, 
hypoglycemia was more common among hip fracture cases (12.0%) compared to 
non-cases (3.8%); the multivariable OR for hypoglycemia-fracture association 
adjusted for the above covariates was 1.81 (95% CI: 1.40-2.34). CONCLUSIONS: 
These results suggest that SU may be associated with increased risk of hip 
fracture in elderly men and women with diabetes, possibly related to elevated 
risk of hypoglycemia-induced falls. These findings need to be confirmed in 
future studies which should also further investigate the interrelationships of SU 
use with hypoglycemia, falls and fractures.  
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OBJECTIVES: Evaluate the external predictive power of the REVEAL HCV risk-
prediction model for HCC using data from the Veterans’ Administration [VA]. 
METHODS: The REVEAL investigators in Taiwan developed a risk-prediction 
model for HCC which has not been validated outside of Taiwan. The VA 
maintains a Clinical Case Registry [CCR] for approximately 360,000 patients with 
HCV infections which summarizes the utilization, diagnostic and lab value data 
for each patient going back to 1999. The patient’s initial HCV diagnosis date is set 
as the index date. VA patients were selected using the REVEAL 
inclusion/exclusion criteria and were then screened for baseline [+/- 6 months of 
index date] data on ALT, ALT/AST ratio, cirrhosis, HCV viral load and genotype. 
The area under ROC was used to evaluate the performance of the risk models. 
RESULTS: A totoal of 47,578 VA HCV patients met study inclusion criteria. The 
VA sample varied significantly from the REVEAL sample in terms of male gender 
and race. The frequency of a baseline viral load > 23,000 IU/mL was 91% in the 
VA sample versus 35% Taiwan sample. The overall incidence of HCC following a 
5-year washout period was 2.1% [n=1,000]. Average REVEAL HCV risk scored 13.2 
[SD=2.4] for non-HCC patients and 14.9 [SD=2.4] in patients with HCC [p<0.0001]. 
The incidence of HCC in VA patients increased monotonically across risk score 
quintiles: 0.48% for the lowest quintile to 4.3% for the highest quintile of risk 
scores. The area under the ROC was 0.6924 when the REVEAL HCV model was 
applied to VA patients. CONCLUSIONS: HCV risk prediction models help 
physicians to identify and motivate high risk patients to initiate treatment. The 
REVEAL risk prediction model is robust even when used for VA patients who 
differ significantly from the Taiwan sample from which the risk score model was 
estimated.  
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BURDEN OF SCHIZOPHRENIA ON SELECTED COMORBIDITIES COSTS  
Lafeuille MH1, Dean J2, Fastenau J3, Panish JM3, Olson WH3, Markowitz M3, Duh MS2, 
Lefebvre P1 
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OBJECTIVES: To evaluate health care costs of patients with schizophrenia and 
specific comorbidities relative to patients without schizophrenia with the same 
comorbidities. METHODS: Medicaid insurance claims databases from five states 
(from 2001-2010) were analyzed. Adults with ≥2 claims for schizophrenia, ≥12 
months of continuous eligibility prior to the first diagnosis (index date), and ≥1 
claim for important comorbidities (substance abuse, obesity, diabetes, metabolic 
syndrome, hyperlipidemia, hypertension, coronary artery disease, congestive 
heart failure, HIV, hepatitis C, and COPD) during the 12 months prior to the index 
date (baseline period) were selected. Patients with schizophrenia were matched 
1:1 with non-schizophrenia control patients based on baseline characteristics 
(propensity scores) and comorbidities common in schizophrenia (exact matching 
factors). All-cause and comorbidity-related monthly health care costs were 
calculated and compared between cohorts using nonparametric re-resampling 
methods. No adjustment was made for multiplicity. RESULTS: A total of 24,652 
schizophrenia and 24,652 patients without schizophrenia were matched. The 
most common comorbidities were hypertension (48.8%), substance abuse (39.1%), 
and diabetes (28.4%). The patients with schizophrenia incurred greater all-cause 
monthly health care costs (cost difference [95% CI], $978 [933-1,024]) and 
comorbidity-related costs (cost difference [95% CI], $288 [269-307]). Schizophrenia 
was also associated with significantly higher comorbidity-related costs in each 
comorbidity subgroup (among the three most common comorbidities: 99% higher 
in hypertension, 293% in substance abuse, and 105% in diabetes). CONCLUSIONS: 
This study show that patients with schizophrenia and comorbidities common in 
patients with schizophrenia had higher all-cause and comorbidity-related health 
care costs compared with patients without schizophrenia with the same 
comorbidities.  
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OBJECTIVES: Estimate annual per-patient medical, drug, and work-loss costs of 
diabetic foot ulcer (DFU) using de-identified administrative claims data. 
METHODS: DFU patients and non-DFU diabetic patients (controls) were 
identified using two databases: ages 65+ from a 5% random sample of Medicare 
beneficiaries (Standard Analytical Files, 2007-2010; DFU N=29,681, controls N= 
201,757) and ages 18-64 from a privately-insured population (OptumInsight, 
2007-2011; DFU N=5,681, controls N=113,337). Patients were required to be 
continuously eligible during the 12 months before (baseline) and 12 months after 
(study period) the index date (ie, the date of the most recent DFU diagnosis 
following 12 months without DFU diagnoses (DFU group); or the date of a 
random medical claim (controls)). DFU patients were matched to controls using 
propensity scores to account for baseline differences in demographics, 
comorbidities, resource utilization, and costs. Medical costs during the study 
period were calculated for both Medicare and privately-insured patients. Because 
drug and work-loss (absenteeism or disability) data were not available for 
Medicare patients, these costs were estimated for the privately-insured sample 
only. Wilcoxon signed-rank tests were used to compare differences in study 
period costs. RESULTS: Data for 4,536 matched pairs of privately-insured  
and 27,878 matched pairs of Medicare patients were analyzed. Incremental 
medical costs for DFU patients were $11,296 for Medicare ($27,040 vs $15,743) and 
$15,329 for privately-insured ($25,931 vs $10,602) patients. Two-thirds (66%) of 
the cost differential among the privately-insured was attributable to excess 
inpatient costs. For Medicare, all places of services (eg, inpatient, 
outpatient/physician, emergency department) contributed approximately 
equally to the medical cost differential. Among the privately-insured, DFU 
patients had excess drug costs of $958 ($4,377 vs $3,420) and excess work-loss 
costs of $3,053 (absenteeism: +$1,490, disability: +$1,564). (Comparisons 
significant at p<0.0001.) CONCLUSIONS: These findings suggest that presence of 
DFU imposes substantial burden on payers beyond that of standard diabetes 
care.  
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OBJECTIVES: Previous research demonstrated that in some patients taking 
opioid analgesics for chronic pain there were significantly higher costs among 
those with concurrent exposures to CYP450-metabolized medications with the 
potential to cause a drug-drug interaction (pDDI), compared to matched patients 
without such exposures. The objectives of this study are to evaluate the 
prevalence of and health care costs associated with pDDIs that may cause major 
interactions in patients chronically taking long-acting opioid (LAO) analgesics. 
METHODS: Using the MarketScan® Commercial Database (2008-2010), cohorts 
were constructed of patients who were dispensed LAOs for >=30 days, both with 
and without pDDI exposures. Propensity score matching was used to mitigate 
the impact of selection bias. Costs were analyzed with a linear model for 
differences and a generalized linear model for ratios. RESULTS: Based on the 
final sample of 57,752 patients, the prevalence of major pDDIs was 5.7% in the 
90-day observation period. Oxycodone was the most common opioid among 
these pDDIs pairs, accounting for 57.3% of patients, followed by fentanyl (32.9%), 
methadone (18.3%) and codeine (1.8%). The most common precipitant drugs 
were fluconazole (34.5%), diltiazem (14.0%), clarithromycin (11.4%) and verapamil 
(10.9%). Based on the 99th percentile cost cutoff in the propensity score matched 
cohorts, the estimated mean monthly overall health care costs from the 
multivariate linear model were $3366 and $2757 for the pDDI-major cohort and 
no-pDDI cohort, respectively, a $609 difference. The generalized linear model 
provided similar results, with an estimated cost ratio of 1.232 (p-value < 0.01). 
The difference in monthly health care cost was mainly driven by outpatient 
medical cost ($257 difference, ratio 1.219, p- value <0.01) and inpatient medical 
cost ($289 difference, p-value = 0.11). CONCLUSIONS: Among patients chronically 
taking LAO analgesics, the exposure to major pDDIs is costly and worthy of 
efforts to avoid such exposures.  
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USE  
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OBJECTIVES: Propensity score (PS) is widely used in observational study. It is 
usually estimated over entire study time period. However, pattern of medication 
use is changed over time. The PS which is estimated without taking into account 
time might be biased. Little is known about the effects of time on propensity 
score. This study aims to determine the differences of PS estimated by 
conventional PS and time-specific PS approaches and their effects on estimates 
of treatment effects. METHODS: A retrospective database analysis at a 
University-affiliated hospital in Thailand was used. Patients who aged 18 years 
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or older and were diagnosed as diabetes during July 2008 – June 2011 with 
receiving glucose lowering agent were included. All included patients were 
categorized into thiazolidinedione (TZDs) and non-TZDs groups. PS were 
estimated by conventional and time-specific approaches. In the time-specific 
approach, PS was separately estimated into 3 groups by calendar time. The pair 
t-test was used to compare the PS of both approaches. Patients were matched 
using caliper nearest neighbor matching with no replacement. The multivariate 
Cox proportional hazard model was used to determine the adjusted hazard ratio 
of cardiovascular hospitalizations of TZDs and non-TZDs in matched cohorts. 
RESULTS: A total of 2165 patients were included in this study. Patients were on 
average 58.8 ± 12.7 years of age with 44.5% of male. The average conventional PS 
was 0.198, which was significantly lower than the average time-specific PS of 
0.209.For CVD-related hospitalization, the adjusted hazard ratio (HR) of 
conventional PS-matched cohort was 1.05 (95% confidence interval (CI); 0.38 – 
2.89), while that of time specific PS-matched cohort was 1.12 (95%CI; 0.43 – 2.92). 
CONCLUSIONS: Propensity scores estimated by conventional and time-specific 
approaches were different. The different PS approaches could lead to different 
estimates of treatment effects. 
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THE IMPLICATIONS OF EVALUATING MEDICATION ADHERENCE AT DIFFERENT 
DRUG CLASSIFICATION LEVELS  
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OBJECTIVES: Proportion of days covered (PDC) has gained increased popularity 
as a key measure of medication adherence. The Centers for Medicare and 
Medicaid Services (CMS) now uses PDC to measure medication adherence for 
quality improvement in Medicare Part D. PDC can be calculated at various drug 
classification levels such as a particular drug (e.g. metformin, glipizide) or a 
broad therapeutic class (e.g. all oral anti-diabetes drugs). The objective of this 
analysis is to show how PDC calculations at different drug levels can result in 
varied adherence estimates. METHODS: The analysis used a sample of claims 
data for all oral anti-diabetes drugs from a national pharmacy and defined drug 
levels using Medispan’s Generic Product Identifiers (GPI). Three methods were 
used to calculate PDCs. In method 1, PDC was computed for each GPI6, and then 
rolled up to the patient level using weighted averages. In methods 2 and 3, PDC 
was calculated for the entire therapeutic area of oral anti-diabetes drugs. Method 
2 used GPI6, and method 3 used GPI10 to determine the drugs; any medication 
overlaps between different drugs were ignored to avoid double counting and any 
medication overlaps within the same drug were pushed out to make adjustment 
in the days covered. RESULTS: PDC was 0.64 for method 1 and 0.69 for both 
methods 2 and 3. Compared to method 1, PDCs from method 2 and 3 were 5% 
higher (N= 188,121, P-value < 0.0001). Among patients with 1 or more distinct 
GPI6s, the difference was even bigger – PDCs from method 2 and 3 were 10% 
higher (N= 90,064, P-value< 0.0001) than that from method 1 (0.75 vs. 0.65). 
CONCLUSIONS: PDCs at varied drug levels could lead to different medication 
adherence estimates and impact conclusions about medication adherence, 
especially for patients who switch drugs within a drug class or use combination 
therapies.  
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COMPARISON OF TWO METHODS FOR IDENTIFYING PROBLEMATIC OPIOID USE 
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OBJECTIVES: In recent years, addiction and problematic use of prescription 
opioid analgesic medications has increased. Using medical and pharmacy claims 
data, the purpose of this study was to compare two methods of characterizing 
problematic opioid use among a commercially insured chronic pain patient 
population. METHODS: A national managed care organization provided medical 
and pharmacy data for individuals with chronic pain and an opioid prescription 
fill during calendar years 2009-2011. Members were placed into one of two 
problematic opioid use groups based on the following criteria: “Doctor Shopping” 
(n = 552), defined as the filling of opioid prescriptions from five or more different 
prescribers within 12 months; and “Rapid Dose Escalation” (n = 741), defined as a 
50% increase in opioid dose in the first 3 months of treatment, or 100% increase 
in dose during the 12-month post-period. Groups were compared on the patient 
characteristics of age, gender, Charlson Comorbidity, and region of residence, 
and on the change in health care service utilization and expenditure over an 18-
month period. RESULTS: Members in the Doctor Shopping group were 
significantly more likely to be female than members in the Rapid Dose Escalation 
group (57.1% vs. 51.3%; p < .025), and also incurred significantly greater increases 
in emergency room charges ($810 vs. $265; p < 0.005). The two groups did not 
differ on any remaining demographics or service utilization estimates, including 
inpatient admissions, days, and costs; office visits and costs; outpatient hospital 
visits and costs; total prescription and opioid-specific costs and days’ supply; 
total health care costs; and the Charlson (p’s > 05). CONCLUSIONS: Results 
revealed only slight differences in demographic makeup and health care 
expenditure across the two problematic opioid use groups, suggesting the 
successful identification of a single, homogenous group. The use of either 
method alone would likely underestimate the prevalence of this burgeoning 
problem.  
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THE EFFECT OF REDESIGNED COMPUTERIZED DRUG-DRUG INTERACTION 
ALERTS ON MEDICATION ERRORS AND PRESCRIBING EFFICIENCY  
Chen S1, Zillich AJ1, Melton BL2, Saleem JJ1, Johnson E2, Weiner M1, Russell SA1, McManus 
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OBJECTIVES: Computerized medication alerts, such as drug-drug interaction 
(DDI) warnings, are intended to improve decision-making at the time of 
prescribing and enhance patient safety. The alert interface influences 
prescribers’ perceptions of warnings, but the interface design of DDI alerts is 
largely unstudied. The objectives were to conduct a simulation study to evaluate 
whether design changes reduce medication errors and improve prescribing 
efficiency. METHODS: We conducted a counterbalanced crossover study with 
outpatient prescribers to evaluate two different DDI alert designs. Redesigned 
alerts incorporated human factors principles such as guidelines for warning 
design; the original alert design served as the control. During the simulation, 
Veterans Affairs outpatient prescribers completed three fictional patient cases 
using both the original and the redesigned alerts. We used six clinically relevant 
DDI alerts of varying severity. Prior to data collection, each DDI was assigned 
correct and incorrect actions to evaluate medication errors. The primary 
outcome was medication errors defined as the number of incorrect actions over 
the number of alerts prescribers received. A secondary outcome was prescribing 
efficiency, defined as the time spent reviewing and resolving all alerts within 
one patient case. The original and redesigned alerts were compared using 
McNemar’s test for medication errors and Wilcoxon signed-rank test for 
efficiency. RESULTS: Twenty prescribers (14 physicians, 4 pharmacists, and 2 
nurse practitioners) completed patient cases for both designs. Medication errors 
were significantly reduced with redesigned alerts (27.5%) compared to the 
original alerts (47.4%; p<0.001). Median time spent on redesigned alerts was 52 
seconds compared to 97 seconds for the original alerts (p<0.001), saving 
prescribers 45 seconds per case. CONCLUSIONS: Based on this simulation study, 
incorporating human factor principles into computerized medication alert 
systems may improve prescribing and patient safety. Evaluation of redesigned 
alerts in a clinical setting is needed to understand the effects during actual 
patient care.  
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TO STUDY THE OUTCOME OF HOSPITALIZATION IN ISCHEMIC VERSUS 
HEMORRHAGIC STROKE  
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OBJECTIVES: To assess and compare the functional outcome/recovery of ischemic 
and intracerebral hemorrhage at discharge from hospital, using modified rankin 
scale and barthel index. METHODS: In the present retrospective study, 140 stroke 
patients (110 patients of infarction including patients of Transient Ischemic Attack 
and 30 hemorrhage patients) were enrolled, their medical records studied and were 
compared for risk factors, disability at discharge, groups’ length of stay and 
mortality. Mean scores on both, Modified Rankin Scale (mRS) and Barthel Index (BI) 
were determined at admission and discharge and then compared using paired ttest. 
Ischemic group was also sub-divided into 2 groups on the basis of treatment with 
tissue plasminogen activator (t-PA) and their scores were also compared with same 
test. Good (mRS score <2 and BI score > 60) or poor outcome (mRS score >2 and BI 
score < 60), were distinguished in both the stroke groups using on both scales. 
RESULTS: Ischemic stroke patients had higher mean score on Barthel Index (70.2, 
p=0.0026) and lower mean score on Modified Rankin Scale (2.3, p=0.000) at discharge 
compared to hemorrhage patients (BI score = 36.67 and mRS score = 3.7). 
Hypertension was determined as the most prevalent risk factor in both the stroke 
types. CAD, atrial fibrillation, previous stroke, diabetes mellitus, alcohol were other 
major factors. ~65% ischemic stroke patients were discharged with a good outcome 
whereas only 30% patients in the hemorrhage group were discharged with a good 
outcome. Patients treated with t-PA experienced better outcome than the patients 
managed conservatively. CONCLUSIONS: The results provide evidence of better 
functional outcome and recovery in ischemic stroke patients at discharge and 
greater risk of mortality in patients with intracerebral hemorrhage.  
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OBJECTIVES: Composite endpoints (CEPs) are being used more frequently in 
describing outcomes for trials of drugs in type-2 diabetes. We reviewed the 
literature on CEPs to determine how they have been used to date on currently 
marketed antidiabetics. METHODS: Medline, Embase and Cochrane databases 
and Clinicaltrials.gov were searched for randomized controlled Phase-3 trials of 
currently marketed incretins, which were grouped by class. We sought trials of 
GLP-1 agonists, DPP-4 inhibitors and SGLT-2 inhibitors. CEPs used were identified 
as well as numbers and percentages of patients achieving each, the time of 
measuring the CEPs and the comparison drugs involved in those trials. RESULTS: 
Twelve studies involving 5611 patients provided data. Drug classes included GLP-
1 agonists (exenatide 10 mcg twice daily, exenatide 2 mg weekly, liraglutide 1.2 
mg daily, and liraglutide 1.8 mg daily), DPP-4 inhibitors (sitagliptin 100 mg daily). 
No studies were found in the literature reporting CEPs for SGLT-2 inhibitors. 
Approximately 18% of patients were treated as first line therapy, 55% as second 
line, and 27% as third. Active comparison drugs and background treatments 
included insulin, metformin, sulfonyluyreas, and thiazolidinediones. Eleven 
different CEPs were used (6 with 2 components, 5 with 3 components). All CEPs 
